Mirvetuximab soravtansine

Drug Profile

Mirvetuximab soravtansine

Alternative Names: Anti-FOLR1 monoclonal antibody-maytansinoid conjugate IMGN853; IMGN-853; M9346A-sulfo-SPDB-DM4

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator ImmunoGen
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Folate receptor 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase I/II Endometrial cancer
  • No development reported Solid tumours

Most Recent Events

  • 19 Apr 2017 M.D. Anderson Cancer Center in collaboration with National Comprehensive Cancer Network plans a phase II trial for Breast cancer in USA
  • 28 Dec 2016 Efficacy data from a phase I trial in Ovarian cancer (Platinum-resistant) released by Immunogen
  • 04 Nov 2016 Phase-III clinical trials in Fallopian tube cancer (Monotherapy, Second-line therapy or greater) in USA (IV) (NCT02631876)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top